1. Skip to header
  2. Skip to main
  3. Skip to content
  4. Skip to sidebar
  5. Skip to footer
Posted on Thursday, Apr 1, 2010

miRview Meso Successfully Identifies Malignant Pleural Mesothelioma

Rosetta Genomics recently published an article describing the development and validation process of their line of products known as miRview. The products are the company’s microRNA-based tests for identification of primary origin of metastases. miRview meso is the first single test that accurately differentiates malignant pleural mesothelioma from other carcinomas in the lung and pleura.

Mesothelioma is a cancer of the mesothelial cells, caused by breathing in asbestos fibers that become lodged in the thin membrane that lines and encases the lungs. Mesothelioma is highly aggressive and is resistant to many cancer treatments. Currently there is no known cure for the disease.

Rosetta Genomics’ website states:

Unlike the tests currently available, miRview™ meso is a microRNA-based molecular diagnostic tool that provides a differential diagnosis with:

  • Accuracy
  • Simple interpretation
  • Routine sample preparation

Rosetta explains that miRview meso is easy to use and is designed to assist patients and physicians diagnose cases of cancer of unknown primary (CUP). By identifying the origin of metastasis patients may not need to undergo additional expensive medical tests to identify the primary site of origin. The quick identification of mesothelioma will allow the patient to begin appropriate treatments.

Rosetta Genomics miRview Publication